HIV vaccines: Unmasking myeloid derived suppressor cells

Green, William R.; O’Connor, Megan A.

doi:10.1016/j.ebiom.2020.103063

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic interventions may become increasingly important due to reduced vaccine-mediated immune susceptibility (especially humoral) of this variant in light of extensive epitope changes [35,36]. CCR2 and CCR5 are widely reported to enable trafficking and signaling of immune-dampening myeloid suppressor cells [37][38][39] and reduce vaccine immune responses [40][41][42][43]. Considering this and aberrant myeloid trafficking, including myeloid-derived suppressor cells being a signature of COVID-19 [44,45], CVC use as a vaccine adjuvant may have some specific merit for further research.…”

Section: Introductionmentioning

confidence: 99%

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

et al. 2022

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2) antagonist, an agent previously studied in advanced clinical trials for patients with HIV or nonalcoholic steatohepatitis (NASH), may have the potential to reduce respiratory and cardiovascular organ failures related to COVID-19. Inhibiting the CCR2 and CCR5 pathways could attenuate or prevent inflammation or fibrosis in both early and late stages of the disease and improve outcomes of COVID-19. Clinical trials using CVC either in addition to standard of care (SoC; e.g., dexamethasone) or in combination with other investigational agents in patients with COVID-19 are currently ongoing. These trials intend to leverage the anti-inflammatory actions of CVC for ameliorating the clinical course of COVID-19 and prevent complications. This article reviews the literature surrounding the CCR2 and CCR5 pathways, their proposed role in COVID-19, and the potential role of CVC to improve outcomes.

show abstract